Cancer News

eCancer News
Posted 23 days ago
New treatment for certain metastatic breast cancers approved

The US FDA approved a new treatment for hormone-receptor positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.

Read full article
eCancer News
Posted 26 days ago
Some breast cancer patients may have shorter radiotherapy course

A study showed that a higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 compared to older patients.

Read full article
eCancer News
Posted 26 days ago
Adding radiation to chemotherapy may improve some lung cancer outcomes

According to a small study, for patients with limited metastatic non-small cell lung cancer (NSCLC), adding radiation therapy to chemotherapy with may curb disease progression dramatically.

Read full article
eCancer News
Posted about 1 month ago
Diet and exercise improve outcomes for obese childhood cancer patients

A study has shown that paediatric cancer patients who are obese may have improved treatment outcomes if they follow a diet and exercise, as they can improve chemotherapy effectiveness and reduce the risk of late effects.

Read full article
eCancer News
Posted about 1 month ago
Immunotherapy approved for advanced bladder cancer in Europe

Pembrolizumab, an immunotherapy agent, has been approved for some types of locally advanced or metastatic bladder cancer.

Read full article
eCancer News
Posted about 1 month ago
First gene therapy approved, for acute lymphoblastic leukemia

The US FDA has approved the first gene therapy against certain children and young adult patients with a form of acute lymphoblastic leukemia (ALL). This is a groundbreaking development which may pave the way for more such treatments.

Read full article
eCancer News
Posted about 1 month ago
Seeking clarity on CT scans after lung cancer surgery

A trial did not show a difference in overall survival between patients with non-small cell lung cancer who received CT scans as part of their follow-up, and those who did not.

Read full article
eCancer News
Posted about 1 month ago
Broader use for fulvestrant approved in some breast cancer types

The US FDA has approved the medication for broader use than before, enabling some breast cancer patients to receive it earlier. The approval was based on a phase 3 clinical trial with 462 patients.

Read full article
eCancer News
Posted 2 months ago
Genetic tests not always done when recommended

A study in the US showed that fewer women with history of breast and ovarian cancer take a recommended genetic test, potentially increasing their future cancer risk.

Read full article
Science Daily
Posted 2 months ago
Fertility information and support often lacking

Researchers highlight the lack of information and support around fertility, for many cancer patients who would be candidates for receiving it.

Read full article
eCancer News
Posted 2 months ago
Olaparib approved for maintenance ovarian cancer treatment

The US FDA has approved olaparib tablets for maintenance ovarian cancer treatment for women in complete or partial response to platinum-based chemotherapy.

Read full article
Science Daily
Posted 9 months ago
Less breast cancer radiation has better cosmetic outcomes, say 65+ patients

When breast cancer patients 65 or older were asked, they reported being more satisfied with the cosmetic outcomes of less radiation, in the long term. However, this should be balanced with a slightly higher recurrence risk.

Read full article
MedPage Today
Posted 9 months ago
Combination treatment for HR positive, HER2 positive breast cancer improves outcomes

Adding pertuzumab to a standard regimen for hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer improved progression-free survival. These were the recently announced results of a clinical trial.

Read full article
Reuters
Posted 9 months ago
A system to cool the scalp may help prevent hair loss for breast cancer patients

Women diagnosed with stage 1 or 2 breast cancer used a scalp-cooling system while undergoing chemotherapy, in a clinical trial. The results show that it helped them prevent hair loss. 

Read full article
eCancer News
Posted 9 months ago
Improved response to treatment against breast cancer with BRCA mutation

Adding veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate among patients with locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations. This was achieved without increasing side-effects. 

Read full article
eCancer News
Posted 10 months ago
Grilled meat linked to higher risks for breast cancer patients

Recent findings show that higher consumption of grilled, barbequed, and smoked meat may increase the mortality risk among breast cancer survivors.

Read full article
eCancer News
Posted 10 months ago
Combining breast cancer treatments more than double progression free survival

Adding everolimus to fulvestrant more than doubled progression-free survival for women with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy.

Read full article
eCancer News
Posted 11 months ago
Combination therapy against HR-positive, HER2-negative advanced breast cancer

A clinical trial focused on patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer. Combining buparlisib with fulvestrant improved outcomes, but researchers feel more studies are needed.

Read full article
eCancer News
Posted 11 months ago
Radiation therapy before breast reconstruction may affect quality of life

Many breast cancer patients will consider breast reconstruction after mastectomy. Radiation therapy can alter the tissue around the breast, reportedly increasing women’s concerns.

Read full article
MedPage Today
Posted 11 months ago
Combination therapy for metastatic breast cancer shows improved survival

Progression-free survival doubled in some patients with metastatic breast cancer treated with everolimus plus fulvestrant, compared with fulvestrant alone. These are results from a randomized trial.

Read full article